Context Therapeutics Shares Are Trading Higher After the Company Announced FDA Clearance of Its IND Application for a Phase 1 Clinical Trial of CTIM-76
Context Therapeutics宣布美国食品药品管理局批准其 CTIM-76 1期临床试验的IND申请后,该公司股价走高
Context Therapeutics Shares Are Trading Higher After the Company Announced FDA Clearance of Its IND Application for a Phase 1 Clinical Trial of CTIM-76
Context Therapeutics宣布美国食品药品管理局批准其 CTIM-76 1期临床试验的IND申请后,该公司股价走高
使用浏览器的分享功能,分享给你的好友吧